Cargando…

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307553/ https://www.ncbi.nlm.nih.gov/pubmed/30613421 http://dx.doi.org/10.1136/lupus-2018-000286corr1

Ejemplares similares

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
por: Casey, Kerry A, et al.
Publicado: (2018)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Correction: Type I Interferon Receptor Deficiency in Dendritic Cells Facilitates Systemic Murine Norovirus Persistence Despite Enhanced Adaptive Immunity
por: Nice, Timothy J., et al.
Publicado: (2017)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Correction: Type I Interferon: Potential Therapeutic Target for Psoriasis?
por: Yao, Yihong, et al.
Publicado: (2009)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Correction: Distinct Roles of Type I and Type III Interferons in Intestinal Immunity to Homologous and Heterologous Rotavirus Infections
por: Lin, Jian-Da, et al.
Publicado: (2016)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
por: Peng, Li, et al.
Publicado: (2015)

Author Correction: The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas
por: Manzoni, Marco, et al.
Publicado: (2021)

Correction: Type I IFNs facilitate innate immune control of the opportunistic bacteria Burkholderia cenocepacia in the macrophage cytosol
por: Dorrington, Michael G., et al.
Publicado: (2021)

Correction: SARS-CoV-2 vaccines in patients with SLE
Publicado: (2021)

Correction: Impaired Expression of Type I and Type II Interferon Receptors in HCV-Associated Chronic Liver Disease and Liver Cirrhosis
Publicado: (2014)

B cells at the adaptive-innate immune system interface in SLE
por: Anolik, JH, et al.
Publicado: (2012)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Correction: Induction of PGRN by influenza virus inhibits the antiviral immune responses through downregulation of type I interferons signaling
por: Wei, Fanhua, et al.
Publicado: (2020)

Correction: Kynurenine pathway is altered in patients with SLE and associated with severe fatigue
Publicado: (2019)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Correction: A Longitudinal Study of BCG Vaccination in Early Childhood: The Development of Innate and Adaptive Immune Responses
por: Djuardi, Yenny, et al.
Publicado: (2013)

Author Correction: Bystander CD4(+) T cells: crossroads between innate and adaptive immunity
por: Lee, Hong-Gyun, et al.
Publicado: (2023)

Correction: BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration
por: Loveridge, Carolyn J., et al.
Publicado: (2019)

Correction: The soluble pattern recognition receptor PTX3 links humoral innate and adaptive immune responses by helping marginal zone B cells
por: Chorny, Alejo, et al.
Publicado: (2017)

Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood
por: Günther, Claudia, et al.
Publicado: (2023)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

Cause and consequences of the activated type I interferon system in SLE
por: Eloranta, Maija-Leena, et al.
Publicado: (2016)

Correction to: Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity
por: Zhang, Peng, et al.
Publicado: (2021)

Correction: Salmonella escapes adaptive immune response via SIRT2 mediated modulation of innate immune response in dendritic cells
por: Gogoi, Mayuri, et al.
Publicado: (2020)

Correction: Dysregulation of miRNAs expression levels and disease activity in SLE patients
Publicado: (2018)

Correction to: Transcriptomes of microglia in experimental cerebral malaria in mice in the presence and absence of Type I Interferon signaling
por: Talavera-López, Carlos, et al.
Publicado: (2019)

Correction: Critical Role of an Antiviral Stress Granule Containing RIG-I and PKR in Viral Detection and Innate Immunity
por: Onomoto, Koji, et al.
Publicado: (2013)

Correction: Critical Role of an Antiviral Stress Granule Containing RIG-I and PKR in Viral Detection and Innate Immunity
por: Onomoto, Koji, et al.
Publicado: (2012)

Correction to: Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers
por: Draganov, Dobrin D., et al.
Publicado: (2021)

Correction to: Tetrahedral Framework Nucleic Acid‑Based Delivery of Resveratrol Alleviates Insulin Resistance: From Innate to Adaptive Immunity
por: Li, Yanjing, et al.
Publicado: (2021)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Correction: Patient-reported outcome measures for use in clinical trials of SLE: a review
Publicado: (2018)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Correction: Genetic Control of the Variable Innate Immune Response to Asymptomatic Bacteriuria
por: Hernández, Jenny Grönberg, et al.
Publicado: (2012)

Correction: Loss of a Conserved tRNA Anticodon Modification Perturbs Plant Immunity
por: Ramírez, Vicente, et al.
Publicado: (2016)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tge6g4483i6voc2121c3lu5ij2